The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.

Authors :: Malcikova J
Razga F
Jurcek T
Dvorakova D
Zackova D
Toskova M
Sebejova L
Smardova J
Oltova A
Vankova G
Jurackova L
Trbusek M
Pospisilova S
Mayer J
Racil Z
Source :: Leukemia & lymphoma [Leuk Lymphoma] 2013 Sep; Vol. 54 (9), pp. 2083-7. Date of Electronic Publication: 2013 Feb 01.
Publication Year :: 2013

Subjects :: Antineoplastic Agents therapeutic use
Codon
Disease Progression
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality
Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology
Protein Kinase Inhibitors therapeutic use
Chromosome Aberrations
Drug Resistance, Neoplasm genetics
Fusion Proteins, bcr-abl genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics
Mutation

Full Text Access

Tools